Ergoteles’s Rubius Therapeutics RUBY Stock Holding History
Bought
Maintained
Sold
Other funds holding RUBY
AG
Ergoteles's RUBY Position: Q1 2023 in Review
Ergoteles sold out of Rubius Therapeutics (RUBY) in Q1 2023, closing a stake of 57,747 shares — an estimated $9.9K sold.
Ergoteles first reported a position in RUBY in Q3 2020 and held it in 4 quarters. The position peaked at $293K in Q4 2021. 7 funds tracked by Wall St. Rank hold RUBY as of Q1 2023.
- Ergoteles reported no remaining Rubius Therapeutics position as of Q1 2023 after selling out during the quarter.
- Ergoteles sold 57,747 Rubius Therapeutics shares in Q1 2023, an estimated $9.9K.
- Ergoteles first reported a position in Rubius Therapeutics in Q3 2020 and held it in 4 quarters.
- Ergoteles's Rubius Therapeutics position peaked at $293K in Q4 2021.
- 7 funds tracked by Wall St. Rank held Rubius Therapeutics as of Q1 2023.
Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.